HOME >> MEDICINE >> NEWS
More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine

CHICAGO -- A group of studies published in the January 24 issue of Archives of Internal Medicine add to the growing body of medical literature about the cardiovascular risks that may be associated with the class of pain-relieving drugs known as COX-2 inhibitors. Archives of Internal Medicine is one of the JAMA/Archives journals.

The Celecoxib Rofecoxib Efficacy and Safety in Comorbodities Evaluation Trial (CRESCENT) evaluated the effects of the COX-2 inhibitors and naproxen on 24-hour blood pressure readings in patients with type 2 diabetes, hypertension, and osteoarthritis. Patients were randomly assigned to receive 200 mg of celecoxib (Celebrex; Pfizer Inc., New York) [n= 136], or 25 mg of rofecoxib once daily (Vioxx, Merck & Co., West Point, Penn.) [n = 138], or 500 mg of naproxen twice daily (Naprosyn; Roche Pharmaceuticals, Basel, Switzerland) [n = 130] for 12 weeks. A total of 65 centers from 7 countries participated in this trial from May 2001 to April 2002. Patient evaluations were conducted at the start of the study and 1, 2, 6, and 12 weeks after randomization.

"Reductions in osteoarthritis symptoms, including pain, mobility, and stiffness, were similar in all treatment groups," the researchers found. "The mean (average) 24-hour systolic [top number in blood pressure reading] blood pressure following 6-weeks of therapy was increased significantly by refecoxib but not by celecoxib or naproxen."

"these results suggest the need for careful monitoring and control of blood pressure when NSAIDS (non-steroidal anti-inflammatory drugs) or COX-2 inhibitors are chosen for osteoarthritis management for patients with hypertension and type 2 diabetes and further suggest need for careful evaluation of currently available as well as future COX-2-specific inhibitors and nonspecific NSAIDs in this population," the authors conclude.

(Arch Intern Med. 2005; 165: 161-168. Available post-embargo at

Contact: Jane Shaskan
860-679-4777
JAMA and Archives Journals
24-Jan-2005


Page: 1 2 3 4 5

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. New studies show mixed results on epilepsy drugs and birth defects
3. Brain imaging studies investigate pain reduction by hypnosis
4. Impact of scientific advances on drug studies and membrane research to be explored
5. Two studies find evidence that sunlight may have beneficial influence on cancer
6. Animal studies show stem cells might make biological pacemaker
7. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
8. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
9. Gender and sex hormones affect the brains pain response and more, according to new studies
10. Analysis of tamoxifen studies reveals slight increase of stroke risk
11. Imaging studies clarify brain changes associated with language deficits in autism

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 2017 , ... Happy Living’s mission - to improve the health and wellbeing ... entertaining and delicious worlds of theatre and wines. , After watching Scott Barry ... turn his play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was ...
(Date:9/22/2017)... ... September 22, 2017 , ... "Success Files," a short- and ... Alzheimer’s is a disease estimated to affect the lives of more than 5 ... Alzheimer’s Association, a leading voice in the fight for cure and research into ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg freezing and ... frozen embryos have a slight statistical advantage for live births, frozen eggs offer ... opportunity for women undergoing medical treatment or who are concerned about the decline ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, M.D., ... Professional Member in recognition of his contributions to the ... as a Nephrologist at the practice of Kidney and ... kidney care and hypertension solutions. He has worked in ... of career experience, as well as expertise in kidneys, ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
Breaking Medicine Technology:
Cached News: